LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

<p>Abstract</p> <p>Background</p> <p>15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver me...

Full description

Bibliographic Details
Main Authors: Schimanski Carl, Möhler Markus, Schön Michael, van Cutsem Eric, Greil Richard, Bechstein Wolf, Hegewisch-Becker Susanna, von Wichert Götz, Vöhringer Matthias, Heike Michael, Heinemann Volker, Peeters Marc, Kanzler Stephan, Kasper Stefan, Overkamp Friedrich, Schröder Jan, Seehofer Daniel, Kullmann Frank, Linz Bernhard, Schmidtmann Irene, Smith-Machnow Victoria, Gockel Ines, Lang Hauke, Galle Peter R
Format: Article
Language:English
Published: BMC 2012-04-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/12/144

Internet

http://www.biomedcentral.com/1471-2407/12/144

Similar Items